资讯

Cancer Therapy Advisor8 天
SC Pembrolizumab Appears Non-Inferior to IV Formulation in Advanced NSCLC
Data suggest that SC pembrolizumab is non-inferior to IV pembrolizumab in patients with newly diagnosed, advanced NSCLC.